Yearly Trends of Overactive Bladder Medication Usage.
Kevin J Chua, Hiren V Patel, Alexandra Tabakin...
https://pubmed.ncbi.nlm.nih.gov/37145398/Actively Recruiting
Led by Walter Reed National Military Medical Center · Updated on 2024-08-19
152
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are evaluating treatments for Overactive Bladder Syndrome OAB in postmenopausal women experiencing urinary frequency, urgency, nocturia, with or without urgency urinary incontinence. This condition affects many women over 65 and can impact mental health, sleep, physical activity, productivity, and quality of life. The study compares the effects of vaginal estradiol cream and oral Mirabegron in managing these symptoms. Participants will be randomly assigned to one of two groups for 12 weeks one group will use 0.01% vaginal estradiol cream applied once nightly for two weeks, then three times a week, combined with a daily placebo oral pill the other group will take 50 milligrams of oral Mirabegron once daily with a placebo vaginal cream following the same schedule. After 12 weeks of single therapy, participants can choose to receive both treatments together for an additional 12 weeks. During the study, participants will complete questionnaires about symptom severity, quality of life, and global impressions of severity and improvement. They will keep a 24-hour voiding diary and have their post-void residual measured. Follow-up assessments occur after 12 weeks of single therapy and after the optional combined therapy. The main outcome measured is the change in symptom bother scores after 12 weeks, with additional evaluations on quality of life and urinary symptoms.
CONDITIONS
Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
C
Christopher W Heuer, DO
K
Katherine L Dengler, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Walter Reed National Military Medical Center
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Vaginal Estradiol Cream | Oral Mirabegron |
|---|---|---|
| What is it? | A vaginal cream containing 0.01% estradiol, used as local estrogen therapy to address urinary symptoms associated with overactive bladder in postmenopausal women. | An oral medication (50 mg mirabegron) taken once daily, which acts as a beta-3 adrenergic agonist to relax bladder muscle and reduce symptoms of overactive bladder. |
| Role in this study | Active treatment arm receiving vaginal estradiol cream plus placebo oral pill. | Active comparator arm receiving 50 mg oral mirabegron plus placebo vaginal cream. |
| Primary reason for use | To relieve urinary urgency, frequency, and bother associated with overactive bladder in postmenopausal women by restoring local estrogen effects on bladder and vaginal tissues. | To treat symptoms of overactive bladder, including urinary urgency and frequency, by relaxing bladder muscle via beta-3 adrenoceptor activation. |
| How it is given or performed | Estradiol cream is applied vaginally each night for two weeks, then three times per week thereafter, with a daily oral placebo pill. | Mirabegron is taken orally as a 50 mg tablet every day with a placebo vaginal cream. |
| Evidence status | Multiple trials and systematic reviews show vaginal estrogen reduces urinary symptoms and improves quality of life in postmenopausal women with genitourinary syndrome, though effects on overactive bladder specifically are still under study. | Large meta-analyses and clinical practice guidelines confirm that mirabegron improves symptoms of overactive bladder, including urgency and frequency, with efficacy comparable to anticholinergic drugs. |
| Important risks | Local vaginal estrogen is generally well tolerated; some women may experience vaginal irritation or discharge. Systemic hormone absorption is very low but remains a consideration for women with contraindications to estrogen. | Mirabegron can increase blood pressure and may cause headache, constipation, or urinary tract infections. Cardiovascular risk should be considered in patients with hypertension. |
| Important limitations | While used for genitourinary syndrome of menopause, vaginal estrogen's effect on overactive bladder symptoms may be less robust, and existing studies vary in outcome measures and populations. Women with contraindications to estrogen therapy cannot use this treatment. | Mirabegron can be costly, and some patients may discontinue due to side effects or insufficient symptom relief. Long-term safety data continues to be evaluated. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive either vaginal estradiol cream or oral Mirabegron as a single therapy to manage overactive bladder symptoms.
1 baseline visit and 1 follow-up visit
Duration - 12 weeks
Participants who opt for combined therapy receive both vaginal estradiol cream and oral Mirabegron to manage overactive bladder symptoms.
1 follow-up visit
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kevin J Chua, Hiren V Patel, Alexandra Tabakin...
https://pubmed.ncbi.nlm.nih.gov/37145398/Masaki Yoshida, Koichi Miyamae, Hitoshi Iwashita...
https://pubmed.ncbi.nlm.nih.gov/15013648/Ian Milsom, Karin S Coyne, Sean Nicholson...
https://pubmed.ncbi.nlm.nih.gov/24007713/Gian Marco Rosa, Simone Ferrero, Victor W Nitti...
https://pubmed.ncbi.nlm.nih.gov/26422675/G Lose, E Englev
https://pubmed.ncbi.nlm.nih.gov/10955437/L D Cardozo, B G Wise, C J Benness
https://pubmed.ncbi.nlm.nih.gov/12521832/Joshua S Benner, Michael B Nichol, Eric S Rovner...
https://pubmed.ncbi.nlm.nih.gov/19912188/Michael B Chancellor, Kristen Migliaccio-Walle, Thomas J Bramley...
https://pubmed.ncbi.nlm.nih.gov/24091072/Jipeng Wang, Zhongbao Zhou, Yuanshan Cui...
https://pubmed.ncbi.nlm.nih.gov/30350884/Walter Reed National Military Medical Center
Lead Sponsor